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Mammalian hematopoiesis is a hierarchically organized process in which all types of mature blood
cells are continuously generated from more primitive cells that lack any morphological evidence of
differentiation. However, it is now accepted that this morphologically homogeneous precursor
population consists of multiple distinct subsets of cells. The most primitive of these are deﬁned by
their ability to produce similarly undifferentiated progeny through many cell divisions, in addition
to generating cells with activated differentiation programs. The term hematopoietic stem cell (HSC)
is now conventionally restricted to cells with this long-term self-sustaining ability. Nevertheless,
clonal tracking studies have revealed signiﬁcant heterogeneity in the behavior of such stringently
deﬁned HSCs. Moreover, superimposed on the heterogeneous behavior that can be elicited from
the HSCs present at any given time during development are additional differences that distinguish
HSCs at different times both before and after birth. The latter include changes in the representation
of HSCs that display speciﬁc differentiation programs, as well as changes in their turnover and self-
renewal control. Here, we summarize recent studies characterizing these developmental changes,
some of the mechanisms that control them, and their potential relevance to understanding age-
associated differences in leukemia as well as normal hematopoiesis.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
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The presence in normal adult bone marrow of individual trans-
plantable cells with long-term, renewable multi-lineage differen-
tiation properties was ﬁrst inferred from experiments that made
use of chromosomal markers to identify the regenerated progeny
of the injected donor cells [1,2]. These observations provided the
ﬁrst experimental evidence that a common pool of HSCs persists
throughout adult life. To this day, the only reliable methods to
detect hematopoietic stem cells (HSCs) continue to rely on the
demonstration of their regenerative properties, rather than on
more direct methods. This is due, in part to the instability of any
phenotype thus far identiﬁed and the deﬁning functional proper-
ties of HSCs, as well as the recognition of the molecular and
functional heterogeneity of HSCs in transplantation assays [3].
Some of this heterogeneity now appears to be cell-autonomous
and developmentally determined [4,5], some externally regulated
[6–9] and some likely due to variables not yet identiﬁed.
Therefore, it is perhaps not surprising that a singular molecular
signature permitting the unique and speciﬁc identiﬁcation of HSCs
remains elusive, in spite of the extensive progress made in the
puriﬁcation and molecular characterization of HSCs from different
sources.
The fact that even highly puriﬁed phenotypes of hematopoietic
cells with long-term repopulating ability display heterogeneity in
both their differentiation behavior and in their ability to expand
their numbers underscores the importance of clonal methods and
deﬁned endpoints of regenerative activity to detect and quantify
HSCs. Several experimental approaches have been used to this
end. Viral marking experiments introduced 30 years ago provided
the ﬁrst evidence of heterogeneity in the differentiation behavior
of individual HSCs with long-term repopulating ability [10–12].
However, the methodology available at that time was limited in
sensitivity by the large amount of genomic material required to
identify unique sites of viral integration. Methods to track the
progeny of HSCs in recipients of limiting numbers of repopulating
cells have been used for more than two decades [13] to infer
clonal outputs from input cell doses that repopulated less than
one third of the recipients. Limiting dilution transplantation
strategies are, however, also problematic because of the large
numbers of “negative” recipients that must be set up to obtain a
“positive” recipient repopulated by a single donor cell. Interest-
ingly, a recent study of mice transplanted with apparently limit-
ing numbers of barcoded input cells revealed the presence of
multiple rather than single clones [14]. The introduction over the
last decade of methods to prospectively isolate mouse HSCs (with
44-month repopulating activities) at very high purities (50%)
made medium scale single-cell transplant experiments feasible.
Importantly, the use of this approach provided the ﬁrst robust
evidence of intrinsic heterogeneities in the differentiation pro-
grams displayed by the serially transplanted progeny of individu-
ally tracked HSCs [15–21]. Viral-based strategies to label
individual input HSCs with a unique DNA “barcode” coupled with
massively parallel DNA sequencing methods to detect and quan-
tify their progeny, are now being used to perform longitudinal
tracking studies of much larger numbers of clones expanding
within the same recipient. To date, such cellular barcoding
experiments have conﬁrmed the general patterns of repopulation
obtained from transplants of puriﬁed subsets or single HSCs. Inaddition, they have established the large diversity in growth and
differentiation behavior of individual clones derived from HSCs
obtained at any given stage of development [14,22,23].
These ﬁndings have introduced a new level of complexity into
the historically accepted two dimensional hierarchical model of
hematopoiesis, and also confusion as to the appropriate deﬁnition
of a HSC. Here we restrict the use of this term to refer to cells that
can regenerate and sustain the production of at least one line-
age of mature blood cells for in excess of 4 months and produce
daughter cells with the same properties. This is based on the
ﬁnding that in mice, most cells able to regenerate detect-
able levels of circulating mature granulocytes for 4–6 months
will continue to do so the rest of the life of the mouse and can
regenerate multiple progeny with similar growth properties
[16,18,24]. Accordingly, detection of short-lived mature blood
cells for this extensive period of time following transplantation
is widely used as a surrogate indicator of an accompanying large
scale self-renewal of the original input HSC [9,17]. Notably, this
HSC deﬁnition deviates fundamentally from the still widely
perpetrated concept that mouse HSCs represent a singular cell
state and can generate persistent outputs of both lymphoid and
myeloid cells. Some evidence of heterogeneity in the long-term
outputs of single human cells with hematopoietic repopulating
activity has also been obtained, primarily in patients transplanted
with genetically manipulated autologous cells where clonal
tracking methods are also possible [25–27]. Although a temporal
cut-off for selectively identifying transplantable human hemato-
poietic cells that have long-term self-renewal ability in vivo has
not yet been established.Developmental origin of HSCs
The ﬁrst wave of hematopoiesis in both mice and humans occurs
in the yolk sac and results in the production initially of macro-
phages and mature red blood cells that remain nucleated even
before the circulation of blood begins [28]. Additional mature and
more primitive hematopoietic cell types appear subsequently,
including the ﬁrst lymphoid cells [29,30]. Transplantable cells that
display the self-sustaining properties of HSCs arise even later in
midgestation, predominantly from hemogenic cells with endothe-
lial features that line both dorsal aorta and blood vessels in the
placenta [31]. These HSCs then translocate to the fetal liver and
spleen where their numbers are rapidly ampliﬁed. Just before
birth they migrate again to developing niches in the bone marrow
where HSCs remain concentrated throughout adult life, although
some may also recirculate [32].
Despite the multiple sites of origin of different types of blood cell
precursors during development, including the ﬁnal generation of
HSCs, lineage tracing experiments have suggested that, at least in
mice, all of the HSCs detectable throughout adulthood are derived
from cells that acquire hematopoietic potential before birth. One
such experiment showed that Runx1-Cre-β-gal mouse cells labeled
on embryonic day 9.5 (E9.5) made a very high contribution to the
blood cells being generated 9–12 months later in the adult [33].
Similarly, a different study using a Scl-Cre-YFP lineage tracing
strategy revealed the adult hematopoietic system is derived mostly
from cells labeled at E14.5. In this latter experiment, the efﬁciency
of HSCs marking was only 10%. However, the proportion of
hematopoietic progeny that were derived from the marked cells in
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derived from HSCs marked at E14.5 but left to mature into
adulthood without further manipulation. This result suggests that
de novo generation of HSCs after E14.5 is unlikely [34].Development-associated changes in HSC properties
Both the functional properties and the transcriptional programs of
HSCs have been found to change during development and aging.
Some of these have been causally linked based on the evidence
suggesting that adult HSCs arise directly from fetal cells with HSC
properties, both in situ (as discussed above) and in mice trans-
planted with fetal HSCs [4]. The changes in gene expression
proﬁles include genes whose products have critical roles in fetal
HSCs, but are down-regulated during adulthood, and vice versa
(Table 1). Functional properties affected include their cycling
behavior, differentiated cell outputs and expansion rates when
stimulated (self-renewal) and sensitivity to Steel factor/Stem Cell
Factor (SF/SCF) [35] — SF/SCF being a cytokine required for the
maintenance of adult mouse HSCs in vivo [36], but not for the
generation and expansion of their fetal predecessors [37].
Many of these changes appear coordinated in their timing with
an abrupt switch in HSC behavior that occurs between 3 and 4
weeks of age in mice. During this period, mouse HSCs transition
in a site-independent fashion from being predominantly in an
actively proliferating mode to being mostly quiescent [4]. Recent
evidence suggests that this switch is orchestrated by a concordant
change in the level of expression in HSCs of Cebpa that occurs
between 2 and 4 weeks of age [38]. The fact that the majority of
primitive adult human hematopoietic cells are also quiescent has
been well established for many years [39], as is indirect evidence
that many of those in the fetal liver are actively proliferating [40].
The existence of an early post-natal switch in HSC turnover rates
in humans analogous to that documented in the mouse has been
inferred from evidence of an abrupt change between 1 and 3
years after birth in the rate at which the length of human and
other primate leukocyte telomeres shorten [41,42], an endpoint
believed to serve as a surrogate indicator of prior HSC division
history. Nevertheless, human cord blood HSCs appear to be
exclusively in G0/G1 [43]. This ﬁnding may reﬂect that fact that
HSCs of both mouse and human origin that are in S/G2/M do not
appear to be able to survive in the circulation [44–46] nor be
detected there [47]. Alternatively, the failure to detect humanTable 1 – Genes that are selectively involved in regulating
fetal and adult HSCs in mice.
Gene Function Reference
Sox17 Required for maintenance and self-renewal
of fetal but not adult HSCs
[67,68]
Lin28b Regulates fetal lymphopoiesis and high
fetal HSC self-renewal
[5,69]
Hmga2 Required for high self-renewal in fetal HSCs [5]
Ezh2 Required for maintenance of fetal but not
adult HSCs
[70]
Pten Negatively regulates mTORC2 signaling in
adult, but not fetal HSCs
[71]
Bmi1 Required for maintenance of adult but not
fetal HSCs
[72]
Cebpa Required for adult HSC quiescence [38]cord blood HSCs in S/G2/M may be indicative of a discrepancy
between the mechanisms that regulate HSC properties in humans
and mice, such that most human HSCs transition from an actively
proliferating state to a quiescent state before birth.
Evidence of differences in the regenerative activity of fetal and
adult HSCs in both mice and humans is also longstanding [48,49].
Our group then showed that the rate at which mouse HSCs expand
post-transplant also decreases abruptly in a cell-intrinsic fashion
between 3 and 4 weeks of age in the mouse [4] (Fig. 1). This appears
to be regulated by a decreased level of expression of Lin28, a
negative regulator of let-7miRNA biogenesis, and thereby of Hmga2,
a let-7 target [5]. However, in contrast to Cebpa and Sox17, Hmga2
expression in mouse HSCs does not show a signiﬁcant change
between 3 and 4 weeks of age, suggesting that the regulation of the
fetal HSC self-renewal phenotype by Hmga2 may operate via a
threshold mechanism [5]. However, the extent to which develop-
mentally determined changes in HSC cycling, survival and self-
renewal properties contribute to the differential rate of HSC expan-
sion exhibited by transplanted fetal and adult cells remains to be
clariﬁed. A potentially unifying mechanism could be related to the
greater sensitivity of fetal mouse HSCs to SF/SCF [35].HSCs comprise a heterogeneous compartment of
changing composition throughout development
Strategies for isolating most sources of mouse HSCs at high purity
(50%) based on their surface phenotype have enabled distinct,
stably transmitted HSC differentiation potentialities to be deﬁni-
tively revealed from serial single-cell transplants [16,18,20,21].
We have found it useful to deﬁne 4 subtypes of HSCs (referred to
as α, β, γ, and δ) on the basis of their different contributions to the
total numbers of circulating myeloid vs. lymphoid cells present
4–6 months post-transplant [16]. The marked ﬁdelity with which
this ratio is retained by daughter HSCs suggests that these
differences are intrinsically maintained as distinct “programs”
within individual HSCs and their progeny. Interestingly, only
production of differentiated cells that are characterized by a
strong and continuing output to the mature granulocyte pool
(regardless of their lymphopoietic activity) identify HSCs (primar-
ily α's and β's) with continuing durable self-renewal activity
demonstrable in serial transplants [16,19,20,25]. Notably, the
same HSC differentiation patterns have been conﬁrmed by others,
not only using single-cell transplants [50], but also using non-
limiting transplants and DNA barcoding of the initial cells to
clonally track their mature cell outputs in the same host [22,51].
Nevertheless, departure from the parental program can also be
seen to occur at a measureable frequency, as best documented in
experiments that have used serial single-cell transplants [18].
Taken together, these ﬁndings conﬁrm earlier observations that
robust continuing granulopoietic cell production is a predictive
feature of HSCs with long-term repopulating activity [24]. At the
same time, they invalidate the notion that all HSCs have equiva-
lent multi-lineage differentiation potential that is then variably
elicited due to either intrinsic or extrinsic mechanisms that
display a stochastic component. Rather, these ﬁndings are more
consistent with the establishment within each HSC of a unique
epigenomic signature that sustains similar lineage outputs from
successive generations of daughter HSCs.
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E18.5 FL
E18.5 BM
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α
Fig. 1 – Changes in the mouse hematopoietic stem cell (HSC) pool during development and aging. Adapted from results published
in [18]. Red borders indicate the high cycling and regenerative rates that characterize all HSCs until 3 weeks of age and black
borders indicate all HSCs after 4 weeks of age are quiescent and display lower regenerative activities [4,46]. The sizes of the circles
indicate schematically the changing HSC compartment size. HSC, hematopoietic stem cell; E, embryonic day; FL, fetal liver; BM,
bone marrow; wk, week; yr, year.
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behaviors of individual HSCs, although sustained both in primary and
subsequent transplanted recipients, is different for fetal and adult
sources (Fig. 1). In the developing fetal liver, the lymphoid-deﬁcient
α-HSCs constitute only less than 5% of all HSCs and less than 10% of the
HSCs with durable self-renewal ability. However, these are much more
prevalent (3 more) amongst the initial HSC population that can be
detected in fetal bone marrow (BM) just before birth [18]. Interestingly,
this shift in the composition of the HSC compartment is further
exacerbated in aging mice in parallel with an increasing decline of
mature lymphoid cells in their peripheral blood [18]. Furthermore,
human HSC from elderly donors transplanted into immunodeﬁcient
mice were found to generate a higher proportion of myeloid relative to
lymphoid progeny relative to their young HSC counterparts [52]. The
HSC pool of some strains of aging mice also contains a higher number
of total HSCs, although these are functionally compromised and give
rise to smaller clones in primary and secondary recipients [14,53].
Although an increased representation of α-HSCs coincides with
their colonization of the fetal bone marrow, the mechanism
underlying this change is not understood. Clearly it is unrelated
to the mechanism that alters the cell cycle status of HSCs during
normal development as this latter parameter does not change in
mice until 3 weeks after birth [46] (Fig. 1). One possibility is that
α-HSCs have a higher probability of survival than β-HSCs upon
exposure to the bone marrow microenvironment, or are gener-
ated by conversion from other HSC subtypes. In one study, TGF-β
was found to selectively induce the proliferation of HSCs with
myeloid potential [6], raising the possibility that exposure to
TGF- β (or other cytokines in the bone marrow) might play a role.Recent studies of the differentiation output of transplanted
mouse HSCs have contributed additional dimensions to our
understanding of their heterogeneity by adding erythrocytes
and platelets to the diversity of mature types of progeny
examined [20,21]. Both of these studies suggest that platelet
reconstitution capacity is a property characteristic of HSCs with
durable self-renewal potential. In addition, one of these studies
[21] provided evidence that Lin Sca-1þ c-Kitþ (LSK) CD150þ
CD48 CD34 HSCs with higher platelet outputs can be identiﬁed
based on their expression of von Willebrand factor (vWF). vWF-
negative HSCs produced lymphoid cells but were deﬁcient in
platelet and myeloid cell production and appear to be enriched
for γ/δ- (myeloid-deﬁcient) HSCs, whereas vWFþ HSCs appear to
include or resemble both α- and β-HSCs. In addition, vWFþ HSCs
readily gave rise to vWF-negative HSCs, whereas the converse was
rarely seen, suggesting a hierarchical relationship between the
two subtypes and consistent with previous ﬁndings that α- and
β-HSCs can give rise to γ/δ-HSCs, but not vice versa [16].Implications for the origin of pediatric hematologic
malignancies
Leukemia is the most prevalent malignancy in children, account-
ing for roughly one-third of all childhood cancers [54]. Interest-
ingly, the incidence rates for leukemia by age comprise a bimodal
distribution, peaking around 5 years of age and gradually decreas-
ing thereafter, and then increasing again in older individuals [54].
B-lineage acute lymphoblastic leukemia (B-ALL) and myeloid
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forms of leukemia in children. Genetic evidence from analysis of
newborn blood spots suggests that in these diseases, the driver
mutations and/or pathogenomic chromosomal rearrangements
are frequently already present before birth [55]. Moreover, studies
of twins with concordant childhood leukemia have revealed the
presence of the same unique acquired mutations in their leukemic
cells, suggesting that the lesion arose in utero when they still
shared a circulation [55]. In addition, in young children, leukemia
manifests predominantly as a lymphoid disease, whereas myeloid
leukemia is more common in adults. The genetic lesions identiﬁed
as causative also differ between pediatric and adult cancers; for
example, the fusion oncogene TEL-AML1 is found in 25% of
pediatric ALL [56], but is rare in adult ALL [57]. In contrast, the
fusion oncogene BCR-ABL1 is found in up to 40% of adult ALL, but
in only 3% of childhood leukemias [58]. The decline in the
incidence of leukemia after early childhood, along with the
different mutational spectrum and cellular makeup of pediatric
leukemias compared to those that appear in adults, raises the
possibility that changes in the cells that can give rise to leukemia,
or the microenvironment that supports them (or both) may be
contributing determinants.
Pathological conditions unique to children, suggesting that the
cells which initiate and/or propagate leukemia in that age group
are regulated differently from their adult counterparts, include
certain pediatric myeloproliferative diseases and leukemias that
resolve spontaneously. A megakaryoblastic leukemia associated
with Down syndrome, known as the transient myeloproliferative
disorder (TMD), can progress to myeloid leukemia but frequently
spontaneously resolves within the ﬁrst few months of life [59].
Cells that make up the TMD in nearly all Down syndrome patients
have genetic lesions leading to the production of a truncated
protein for the transcription factor GATA1 (termed GATA1s).
Megakaryocytes derived from yolk sac and E14.5 fetal liver
GATA1s knock-in mice show increased proliferation in vitro
relative to their wild-type counterparts, whereas those derived
from newborn and adult bone marrow proliferate similar to wild-
type, mirroring the spontaneous resolution of TMD in patients
[60]. In addition, spontaneous regression in the absence of
treatment has occasionally been documented in cases of juvenile
myelomonocytic leukemia involving RAS signaling pathway muta-
tions [61]. Finally, patients with Noonan syndrome, which is
characterized by activating mutations in the PTPN11 gene, are at
increased risk for developing juvenile myelomonocytic leukemia
in early childhood, but this propensity for leukemia development
declines to baseline later in life despite the persistence of the
congenital genetic abnormalities [62].
A recent study from our group identiﬁed that the higher
expression of Lin28b and Hmga2 in mouse fetal HSCs underlies
their heightened ability to expand their own numbers in vivo
relative to their adult counterparts [5]. Overexpression of LIN28B
and/or of HMGA2 has been reported in various human cancers,
whereas let-7 miRNAs, whose biogenesis is repressed by LIN28
proteins, are known tumor suppressors [63–65]. It is therefore
inviting to speculate that the higher expression of LIN28B and
HMGA2 in fetal HSCs makes them more susceptible to transfor-
mation, although this question has not yet been investigated in
human cells. The idea that an intrinsically programmed decline in
the expression of these genes during development leads to
changes in HSCs that make them less able to initiate or propagateleukemia is consistent with reports of a decreased incidence of
leukemia after early childhood, as well as the ability of some
childhood leukemias to spontaneously resolve. There is also an
example of primitive blood cell precursors in the human neonate
being more susceptible to transformation than their adult coun-
terparts, as shown by transduction experiments with the acute
myeloid leukemia oncogene MLL-AF9 [66].
In summary, during early development and throughout aging,
signiﬁcant changes occur in the composition of the HSC pool in
mice, as well as in their shared HSC properties. Accruing evidence
suggests similar age-associated changes may affect human HSC
behavior. Delineation of changes in human HSC properties during
ontogeny and their molecular basis may help to explain the
relatively high incidence of childhood leukemias, as well as why
many of their features differ from hematopoietic malignancies
that arise much later in adults. Finally, a greater understanding of
mechanisms regulating the higher self-renewal potential of fetal
HSCs may lead to new methods to expand HSCs for clinical use,
for example in the setting of gene therapy.Acknowledgments
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